TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02173938

Intervention type: OTHER
Intervention: Tobacco Dependence Treatment
Description: face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
Study: NCT02891109

Intervention type: BIOLOGICAL
Intervention: Biological tests
Description: From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry

Intervention type: BIOLOGICAL
Intervention: Biological tests
Description: From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
Study: NCT01706796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Oral solution, single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Immediate Release Tablet, single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (short duration, MR1), single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (long duration, MR2), single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (short duration, MR1), single dose, fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: Modified Release Tablet (long duration, MR2), single dose, fed
Study: NCT04245072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent angiography
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent angiography
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Refractometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Refractometry
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmoscopy
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmoscopy
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OKT
Description: Ophthalmic examination

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OKT
Description: Ophthalmic examination
Study: NCT02127710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094
Description: AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
Study: NCT02063711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Study: NCT02228434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring and Tailored prescription

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy 10 program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specified nutrition education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Education
Study: NCT01321060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter drainage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
Study: NCT02979197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OE 10 mg amlodipine besylate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OE 10 mg amlodipine besylate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OE 200 mg celecoxib capsule

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo for OE amlodipine besylate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo for OE celecoxib capsule

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo for OE celecoxib capsule
Study: NCT02744703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total-etch adhesive
Description: comparator use of total-etch adhesive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPE-T
Description: experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: self-etch adhesive
Description: comparator use of total-etch adhesive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPE-S
Description: experimental group
Study: NCT01254071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
Description: In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
Study: NCT03049618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study: NCT03643159

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Abilify MyCite - Digital Medicine System
Description: The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole or other oral antipsychotics
Description: For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole or other oral antipsychotics
Description: For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
Study: NCT02605304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir
Description: Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir
Description: Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally.
Study: NCT02081183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
Study: NCT03356158

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Injection, q.w., 20 mg: 100 ml
Study: NCT00601523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: ER 0.375-4,5 mg
Study: NCT02702193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET-R/Healthy Home
Description: SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
Study: NCT02558738

Intervention type: DEVICE
Intervention: ear spray

Intervention type: DEVICE
Intervention: ear spray
Study: NCT02081183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Maintenance Phase
Description: 0.5-1 g/m\^2 IV pulse once every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Induction Phase
Description: 0.5 - 1 g/m\^2 IV pulse once per month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Induction Phase
Description: 0.5 - 1 g/m\^2 IV pulse once per month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
Study: NCT04339075

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
Study: NCT00041717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fampridine-SR
Description: 25mg bid (twice daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02329873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation exercise training
Description: The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
Study: NCT00629694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenoidectomy, myringotomy, tubes insertion
Description: adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-M
Description: adenoidectomy and myringotomy alone
Study: NCT04210336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAPILOCARE
Description: Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
Study: NCT02415296

Intervention type: OTHER
Intervention: stage 1
Description: The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.

Intervention type: OTHER
Intervention: stage 2
Description: The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.

Intervention type: OTHER
Intervention: stage 3
Description: The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
Study: NCT03363828

Intervention type: DRUG
Intervention: Estrofem
Description: Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
Study: NCT02995681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehab
Description: Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehab
Description: Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
Study: NCT02851680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Study: NCT00676273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-Obturator (TVT-O)
Description: sub urethral sling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-Secur (TVT-S) (Hammock method)
Description: suburethral sling
Study: NCT01124058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR.
Study: NCT03992313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facility-based HCV rapid test
Description: HCV rapid tests will be done in the health center

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmatic HCV viral load
Description: HCV viral load will be done in provincial hospital on plasma using GenXpert

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS HCV viral load
Description: HCV viral load will be done in Phnom Penh by DBS using Omunis kit
Study: NCT01811368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibritumomab tiuxetan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total nodal irradiation
Description: Undergo TLI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV
Study: NCT00989157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Single dose of 60 mg of duloxetine
Study: NCT02773290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Weekly SC administration
Study: NCT00000304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: 15 mg for first 8 weeks and 30 mg for 2nd 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Amphetamine
Description: 30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00788073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STX209
Description: Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
Study: NCT00599950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C and Photorefractive keratectomy (PRK)
Description: Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitomycin C and Photorefractive keratectomy (PRK)
Description: Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
Study: NCT04044495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal brain imaging (MRI)
Description: Multimodal brain imaging (MRI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: 7 days actimetry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Diary
Description: 7 days Record of sleep and wake cycle
Study: NCT04016233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir douche
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study: NCT02364622

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tranditional fiberoptic bronchoscopy
Description: The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified fiberoptic bronchoscopy
Description: The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible Trachway intubating stylet
Description: The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
Study: NCT01161784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics fermented milk
Description: 80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient drink
Description: 80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
Study: NCT03243942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
Study: NCT02637154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing method

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Standard Education material will be used
Study: NCT01454960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support: Accountable Justification
Description: Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support: Accountable Justification
Description: Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support: Accountable Justification
Description: Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support: Accountable Justification
Description: Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).